摘要
目的 探讨阿立哌唑联合碳酸锂治疗双相情感障碍躁狂发作的临床疗效和安全性.方法 将64例双相情感障碍躁狂发作患者随机分为两组,每组32例.两组均口服碳酸锂治疗,研究组在此基础上联合阿立哌唑治疗.观察6周.于治疗前及治疗第1周、2周、4周、6周末采用Bech-Rafaelsen躁狂量表评定临床疗效,副反应量表评定不良反应.结果 研究组碳酸锂应用剂量显著低于对照组（t=7.95,P＜0.01）,且显效时间显著早于对照组（t=12.37,P＜0.01）.治疗后两组Bech-Rafaelsen躁狂量表评分均较治疗前显著下降（P＜0.01）,研究组治疗各时段均较对照组下降更显著（P＜0.01）;治疗6周末,研究组显效率87.50%、总有效率93.75%,对照组为84.38%、96.88%,两组比较差异无显著性（P＞0.05）;两组不良反应均轻微,治疗各时段副反应量表评分差异无显著性（P＞0.05）.结论 碳酸锂联合阿立哌唑治疗双相情感障碍躁狂发作疗效显著,较单用碳酸锂治疗起效更快,安全性更高.
Objective To explore the efficacy and safety of aripiprazole combined with lithium carbonate in the treatment of manic episode of bipolar disorder. Methods Sixty-four patients with manic episode of bipolar disorder were randomly assigned to two groups of 32 ones each. Both groups took orally lithium carbonate and research group was plus aripiprazole for 6 weeks. Efficacies were assessed with the Bech-Rafaelsen Mania Rating Scale （BRMS） and adverse reactions with the Treatment Emergent Symptom Scale （TESS） before treatment and at the end of the 1^st, 2^nd, 4^th and 6^th week. Results The application dose of lithium carbonate was significantly lower （t=7.95,P〈0.01） and taking-effect quicker （t=12.37,P〈 0.01） in research than control group. The BRMS scores of both groups lowered more significantly after treatment compared with pretreatment （P〈0. 01）, so did those in each period in research than control group （P〈0.01） ; at the end of the 6th week, obvious and total effective rate were respectively 87.50% and 93. 75% in research and 84. 38% and 96.88% in control group, which showed no significant differences （P〈0.05） ; adverse reactions of both groups were mild and there were no significant differences in TESS scores in each period （P〈0.05）. Conclusion Lithium carbonate combined with aripiprazoles has an evident effect on manic episode of bipolar disorder, takes effect more rapidly than single lithium carbonate and has higher safety.
出处
《临床心身疾病杂志》
CAS
2012年第4期325-327,共3页
Journal of Clinical Psychosomatic Diseases
